Drug Shortage Report for PAMIDRONATE DISODIUM OMEGA 9 MG/ML
| Report ID | 255294 |
| Drug Identification Number | 02249685 |
| Brand name | PAMIDRONATE DISODIUM OMEGA 9 MG/ML |
| Common or Proper name | PAMIDRONATE DISODIUM |
| Company Name | OMEGA LABORATORIES LIMITED |
| Market Status | MARKETED |
| Active Ingredient(s) | PAMIDRONATE DISODIUM |
| Strength(s) | 9MG |
| Dosage form(s) | SOLUTION |
| Route of administration | INTRAVENOUS INTRAVENOUS |
| Packaging size | 1 x 10 mL vial / fiole |
| ATC code | M05BA |
| ATC description | DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION |
| Reason for shortage | Disruption of the manufacture of the drug. |
| Anticipated start date | 2025-10-13 |
| Actual start date | |
| Estimated end date | 2025-10-24 |
| Actual end date | 2025-10-15 |
| Shortage status | Resolved |
| Updated date | 2025-10-16 |
| Company comments | |
| Health Canada comments | |
| Tier 3 Status | No |
| Contact Address | 11177 HAMON MONTREAL, QUEBEC CANADA H3M 3E4 |
| Company contact information | info@omegalaboratory.com - 1-800-363-0584 |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
| Version Number | Date Updated | Language | |
|---|---|---|---|
| v29 | 2025-10-16 | French | Compare |
| v28 | 2025-10-16 | English | Compare |
| v27 | 2025-10-14 | English | Compare |
| v26 | 2025-10-07 | French | Compare |
| v25 | 2025-10-07 | English | Compare |
| v24 | 2025-10-07 | English | Compare |
| v23 | 2025-10-07 | French | Compare |
| v22 | 2025-10-07 | English | Compare |
| v21 | 2025-10-07 | English | Compare |
| v20 | 2025-10-01 | French | Compare |
| v19 | 2025-10-01 | English | Compare |
| v18 | 2025-09-18 | French | Compare |
| v17 | 2025-09-18 | English | Compare |
| v16 | 2025-09-16 | English | Compare |
| v15 | 2025-08-29 | French | Compare |
| v14 | 2025-08-29 | English | Compare |
| v13 | 2025-08-27 | English | Compare |
| v12 | 2025-08-26 | French | Compare |
| v11 | 2025-08-26 | English | Compare |
| v10 | 2025-08-18 | French | Compare |